Acute myeloid leukemia: current progress and future directions
H Kantarjian, T Kadia, C DiNardo, N Daver… - Blood cancer …, 2021 - nature.com
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
Updates on targeted therapies for acute myeloid leukaemia
S Kayser, MJ Levis - British journal of haematology, 2022 - Wiley Online Library
In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …
leukaemia (AML) has led to remarkable advances in our understanding of the disease …
How I treat acute myeloid leukemia in the era of new drugs
CD DiNardo, AH Wei - Blood, The Journal of the American …, 2020 - ashpublications.org
The acute myeloid leukemia (AML) treatment landscape has changed substantially since
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …
[HTML][HTML] Moving toward individualized target-based therapies in acute myeloid leukemia
A Bazinet, HM Kantarjian - Annals of Oncology, 2023 - Elsevier
Highlights•AML is a highly heterogeneous disease and warrants an individualized
approach.•The advent of effective low-intensity regimens has improved outcomes in older …
approach.•The advent of effective low-intensity regimens has improved outcomes in older …
New targeted agents in acute myeloid leukemia: new hope on the rise
SR Bohl, L Bullinger, FG Rücker - International journal of molecular …, 2019 - mdpi.com
The therapeutic approach for acute myeloid leukemia (AML) remains challenging, since
over the last four decades a stagnation in standard cytotoxic treatment has been observed …
over the last four decades a stagnation in standard cytotoxic treatment has been observed …
Advances in acute myeloid leukemia: recently approved therapies and drugs in development
Simple Summary Acute myeloid leukemia (AML) is one of the most common types of
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …
Precision therapy for acute myeloid leukemia
X Yang, J Wang - Journal of hematology & oncology, 2018 - Springer
Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease.
Despite advances in understanding the pathogenesis of AML, the standard therapy …
Despite advances in understanding the pathogenesis of AML, the standard therapy …
[HTML][HTML] The clinical impact of the molecular landscape of acute myeloid leukemia
S Kayser, MJ Levis - Haematologica, 2023 - ncbi.nlm.nih.gov
Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
Recent drug approvals for acute myeloid leukemia
C Lai, K Doucette, K Norsworthy - Journal of hematology & oncology, 2019 - Springer
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …
incidence that increases with age, and a generally poor prognosis. The disease is clinically …
New directions for emerging therapies in acute myeloid leukemia: the next chapter
Conventional therapy for acute myeloid leukemia is composed of remission induction with
cytarabine-and anthracycline-containing regimens, followed by consolidation therapy …
cytarabine-and anthracycline-containing regimens, followed by consolidation therapy …